Drugs Today (Barc). 2007 Nov;43(11):749-58. doi: 10.1358/dot.2007.43.11.1131763.


Maraviroc, first in a new pharmacological class of antiretroviral agents known as CCR5 antagonists, has been approved by the U.S. Food and Drug Administration for the treatment of HIV-infected adult patients who are infected with only CCR5-tropic HIV-1 virus and who have HIV-1 strains resistant to multiple antiretroviral agents. Maraviroc has demonstrated in vitro activity against a wide range of CCR5 tropic clinical isolates, including those resistant to the four currently existing drug classes of antiretroviral agents. In the two pivotal phase III studies, MOTIVATE-1 and -2, maraviroc, in combination with optimized background therapy (OBT), demonstrated superior virologic and immunologic treatment outcomes than OBT alone in treatment-experienced patients infected with CCR5-tropic HIV-1. In these studies, maraviroc also demonstrated acceptable safety and tolerability profiles with adverse events and discontinuation rates in general comparable to those noted in the placebo arms.

Publication types

  • Review

MeSH terms

  • Animals
  • Controlled Clinical Trials as Topic
  • Cyclohexanes / adverse effects
  • Cyclohexanes / pharmacology*
  • Cyclohexanes / therapeutic use
  • Drug Interactions
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Female
  • Food-Drug Interactions
  • HIV Fusion Inhibitors / adverse effects
  • HIV Fusion Inhibitors / pharmacology*
  • HIV Fusion Inhibitors / therapeutic use
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects
  • Humans
  • Male
  • Maraviroc
  • Triazoles / adverse effects
  • Triazoles / pharmacology*
  • Triazoles / therapeutic use


  • Cyclohexanes
  • HIV Fusion Inhibitors
  • Triazoles
  • Maraviroc